businesswire.com/news/home/2022…

Is your favorite gene Jak2? Answer our poll!

It’s a great day to love Jak-Stat signaling….

I’m excited to have started this new role as Chief Medical Officer of ⁦AjaxTherapeutics⁩, focused on developing new medicines for patients with myeloid neoplasms. It is a terrific team and brilliant group of founders led by ⁦Ross Levine⁩ #MPNsm #JAK2 ajaxtherapeutics.com/ajax-therapeut…

TeamAjax is incredibly excited to announce that David Steensma, MD has joined us as our first Chief Medical Officer. He is an ideal choice to lead our efforts to deliver next-generation therapies to MPN patients. ajaxtherapeutics.com/ajax-therapeut…

If you follow David Steensma, MD, our new CMO, give us a follow here if you want to be in the know on all things JAK. There is a reason that the Janus kinases are kings of RTK signaling...

All Jak kinases are cool. BUT Jak2 is the one which Reggie Jackson said is "the straw that stirs the drink..."

Fun JAK2 fact; the homodimeric type I cytokine receptors (EPOR, MPL, GCSFR, LeptinR, GHR) all either exclusively or predominantly engage JAK2 as their partner signaling kinase>other JAK kinases. They have good taste, those receptors..

Another fun fact about JAK2. Murine human JAK2 are 91% homologous at an AA level, and are largely able to function similarly in murine/human cells. But human JAK2 is really hard to clone, presumably due to nucleotide secondary structure (try STABL cells at 30 degrees).

Today is a great day to learn, talk and think about JAK2.

Stay tuned, exciting updates from Team Ajax soon!

Its a good week to be a JAK2 enthusiast!

Ajax Announcement #2. The IND for our lead molecule, AJ-101095, a potent selective type II JAK inhibitor, has been cleared by the FDA. Next stop->clinic. Let's go!. ajaxtherapeutics.com/ajax-therapeut… David Steensma, MD

We've been busy at AjaxTherapeutics! IND application for first type II JAK2 inhibitor (AJ1-11095) to go into clinical trials, based on pre-clinical work done Ross Levine lab and with a molecule designed in collaboration with Schrödinger Therapeutics, has been cleared by U.S. FDA:

endpts.com/ajax-gets-95m-…

biopharmadive.com/news/ajax-seri…